NYSE:RMD - ResMed Stock Price, News, & Analysis

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed announced a quarterly dividend on Friday, October 26th. Shareholders of record on Thursday, November 8th will be given a dividend of $0.37 per share on Thursday, December 13th. This represents a $1.48 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date is Wednesday, November 7th. View ResMed's Dividend History.

ResMed Inc. (NYSE:RMD) posted its quarterly earnings data on Thursday, October, 25th. The medical equipment provider reported $0.81 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.80 by $0.01. The medical equipment provider had revenue of $588.28 million for the quarter, compared to analyst estimates of $576.66 million. ResMed had a return on equity of 26.29% and a net margin of 13.94%. View ResMed's Earnings History.

ResMed is scheduled to release their next quarterly earnings announcement on Monday, January 28th 2019. View Earnings Estimates for ResMed.

9 brokerages have issued 1 year price targets for ResMed's shares. Their predictions range from $127.00 to $127.00. On average, they expect ResMed's stock price to reach $127.00 in the next year. This suggests a possible upside of 12.5% from the stock's current price. View Analyst Price Targets for ResMed.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ResMed.

Media coverage about RMD stock has been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ResMed earned a daily sentiment score of 1.9 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the company's share price in the immediate future.

Some companies that are related to ResMed include Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ABIOMED (ABMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Haemonetics (HAE), Insulet (PODD), ICU Medical (ICUI), Penumbra (PEN), Globus Medical (GMED), Integra Lifesciences (IART), Cantel Medical (CMD) and Merit Medical Systems (MMSI).

ResMed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.22%), BlackRock Inc. (7.85%), FMR LLC (5.52%), Capital World Investors (4.93%), Baillie Gifford & Co. (3.40%) and Bank of New York Mellon Corp (1.15%). Company insiders that own ResMed stock include Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

RMD stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, FMR LLC, Mitsubishi UFJ Trust & Banking Corp, Great Lakes Advisors LLC, First Trust Advisors LP, Korea Investment CORP, Allianz Asset Management GmbH and West Coast Financial LLC. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas and Ronald R Taylor. View Insider Buying and Selling for ResMed.

RMD stock was acquired by a variety of institutional investors in the last quarter, including Deutsche Bank AG, AQR Capital Management LLC, Renaissance Technologies LLC, Schroder Investment Management Group, Marshall Wace LLP, BlackRock Inc., Canada Pension Plan Investment Board and NN Investment Partners Holdings N.V.. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of RMD stock can currently be purchased for approximately $112.90.

ResMed has a market capitalization of $15.67 billion and generates $2.34 billion in revenue each year. The medical equipment provider earns $315.58 million in net income (profit) each year or $3.53 on an earnings per share basis. ResMed employs 5,940 workers across the globe.

The official website for ResMed is http://www.resmed.com.

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]